Pharmacokinetics, Metabolism, and Excretion of the Intestinal Peptide Transporter 1 (SLC15A1)-Targeted Prodrug (1S,2S,5R,6S)-2-[(2′S)-(2-Amino)propionyl]aminobicyclo[3.1.0.]hexen-2,6-dicarboxylic acid (LY544344) in Rats and Dogs: Assessment of First-Pass Bioactivation and Dose Linearity
暂无分享,去创建一个
[1] Gordon L. Amidon,et al. Targeted prodrug design to optimize drug delivery , 2000, AAPS PharmSci.
[2] A. Bado,et al. Regulation of the Oligopeptide Transporter, PEPT-1, in DSS-Induced Rat Colitis , 2007, Digestive Diseases and Sciences.
[3] P. Artursson,et al. Regional levels of drug transporters along the human intestinal tract: co-expression of ABC and SLC transporters and comparison with Caco-2 cells. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[4] Teruko Imai,et al. Substrate Specificity of Carboxylesterase Isozymes and Their Contribution to Hydrolase Activity in Human Liver and Small Intestine , 2006, Drug Metabolism and Disposition.
[5] N. Fujii,et al. Transport Characteristics of a Novel Peptide Transporter 1 Substrate, Antihypotensive Drug Midodrine, and Its Amino Acid Derivatives , 2006, Journal of Pharmacology and Experimental Therapeutics.
[6] C. Klaassen,et al. Tissue distribution and thyroid hormone regulation of Pept1 and Pept2 mRNA in rodents , 2006, Peptides.
[7] D. McKinzie,et al. Improved Bioavailability of the mGlu2/3 Receptor Agonist LY354740 Using a Prodrug Strategy: In Vivo Pharmacology of LY544344 , 2006, Journal of Pharmacology and Experimental Therapeutics.
[8] Ralph R. Reisfeld,et al. Targeting cell-impermeable prodrug activation to tumor microenvironment eradicates multiple drug-resistant neoplasms. , 2006, Cancer research.
[9] Teruko Imai,et al. Human carboxylesterase isozymes: catalytic properties and rational drug design. , 2006, Drug metabolism and pharmacokinetics.
[10] M. Clay,et al. Dipeptides as effective prodrugs of the unnatural amino acid (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740), a selective group II metabotropic glutamate receptor agonist. , 2005, Journal of medicinal chemistry.
[11] Y. Sai,et al. Biochemical and molecular pharmacological aspects of transporters as determinants of drug disposition. , 2005, Drug metabolism and pharmacokinetics.
[12] C. Muhtz,et al. Effects of a metabotropic glutamate2/3 receptor agonist (LY544344/LY354740) on panic anxiety induced by cholecystokinin tetrapeptide in healthy humans: preliminary results , 2005, Psychopharmacology.
[13] B. Testa. Prodrug research: futile or fertile? , 2004, Biochemical pharmacology.
[14] B. Steffansen,et al. Acyclovir prodrug for the intestinal di/tri-peptide transporter PEPT1: comparison of in vivo bioavailability in rats and transport in Caco-2 cells. , 2004, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[15] Akira Tsuji,et al. Transporter-mediated drug delivery: recent progress and experimental approaches. , 2004, Drug discovery today.
[16] N. Mukhopadhyay,et al. Genetic Polymorphisms in Human Proton-Dependent Dipeptide Transporter PEPT1: Implications for the Functional Role of Pro586 , 2004, Journal of Pharmacology and Experimental Therapeutics.
[17] B. Testa,et al. Lessons learned from marketed and investigational prodrugs. , 2004, Journal of medicinal chemistry.
[18] K. Hillgren,et al. Comparison of human and monkey peptide transporters: PEPT1 and PEPT2. , 2004, Molecular pharmaceutics.
[19] Wolfgang Sadee,et al. 5′-Amino Acid Esters of Antiviral Nucleosides, Acyclovir, and AZT Are Absorbed by the Intestinal PEPT1 Peptide Transporter , 1998, Pharmaceutical Research.
[20] M. Brandsch,et al. The intestinal H+/peptide symporter PEPT1: structure-affinity relationships. , 2004, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[21] L. Levine,et al. LY354740, an mGlu2/3 Receptor Agonist as a Novel Approach to Treat Anxiety/Stress , 2003, Stress.
[22] A. Mitra,et al. Current prodrug strategies via membrane transporters/receptors , 2002, Expert opinion on biological therapy.
[23] S. Frokjaer,et al. Transport of peptidomimetic drugs by the intestinal Di/tri-peptide transporter, PepT1. , 2002, Pharmacology & toxicology.
[24] J. L. Herman,et al. The disposition, metabolism, and pharmacokinetics of a selective metabotropic glutamate receptor agonist in rats and dogs. , 2002, Drug metabolism and disposition: the biological fate of chemicals.
[25] H. Saito,et al. Recognition of L-amino acid ester compounds by rat peptide transporters PEPT1 and PEPT2. , 1999, The Journal of pharmacology and experimental therapeutics.
[26] A. Guo,et al. Direct evidence for peptide transporter (PepT1)-mediated uptake of a nonpeptide prodrug, valacyclovir. , 1998, Biochemical and biophysical research communications.
[27] P. Sinko,et al. Carrier‐mediated intestinal absorption of valacyclovir, the L‐valyl ester prodrug of acyclovir. 1. Interactions with peptides, organic anions and organic cations in rats , 1998, Biopharmaceutics & drug disposition.
[28] M Hosokawa,et al. The mammalian carboxylesterases: from molecules to functions. , 1998, Annual review of pharmacology and toxicology.
[29] D. Schoepp,et al. LY354740 is a Potent and Highly Selective Group II Metabotropic Glutamate Receptor Agonist in Cells Expressing Human Glutamate Receptors , 1997, Neuropharmacology.